{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Zelenoleucel",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A preparation of allogeneic multi-tumor-associated antigen (MultiTAA)-specific T-lymphocytes, with potential immunomodulating and antineoplastic activities. Upon administration, zelenoleucel may target and kill tumor cells expressing the TAAs.",
    "fdaUniiCode": "L4D9X59F34",
    "identifier": "C175351",
    "preferredName": "Zelenoleucel",
    "semanticType": "Cell",
    "subclassOf": [
      "C28676"
    ],
    "synonyms": [
      "Allogeneic MultiTAA-specific T-lymphocytes MT-401",
      "Donor-Derived Multi-Tumor-Associated Antigen-specific T Cells",
      "MT 401",
      "MT-401",
      "MT401",
      "ZELENOLEUCEL",
      "Zelenoleucel"
    ]
  }
}